F3Logic’s Blueprint Medicines BPMC Stock Holding History

F3Logic’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,555	Closed	-$1.28M	–	148
2019 Q2	$1.28M	Sell	13,555 -5,000	-27%	-$413K	0.24%	84
2019 Q1	$1.49M	Buy	+18,555	New	+$1.37M	0.32%	76

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

F3Logic's BPMC Position: Q3 2019 in Review

F3Logic sold out of Blueprint Medicines (BPMC) in Q3 2019, closing a stake of 13,555 shares — an estimated $1.28M sold.

F3Logic first reported a position in BPMC in Q1 2019 and held it in 2 quarters. The position peaked at $1.49M in Q1 2019. 219 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

F3Logic reported no remaining Blueprint Medicines position as of Q3 2019 after selling out during the quarter.
F3Logic sold 13,555 Blueprint Medicines shares in Q3 2019, an estimated $1.28M.
F3Logic first reported a position in Blueprint Medicines in Q1 2019 and held it in 2 quarters.
F3Logic's Blueprint Medicines position peaked at $1.49M in Q1 2019.
219 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on F3Logic's 13F filing for Q3 2019, filed 8 Nov 2019.